ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BHC vs VRDN // FORWARD P/E MULTIPLE

Bausch Health Companies Inc. (NYSE) VS. Viridian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BHC 4 — VRDN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. VRDN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BHC VRDN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 7.60% -35.00% +42.60 BHC /roic <GO>
EV/EBITDA & P/E Valuation 10.5x — — TIE /valuation <GO>
Free Cash Flow Yield 22.00% -9.85% +31.85 BHC /fcf-yield <GO>
Operating Margin 17.70% — — TIE /operating-margins <GO>
Net Profit Margin 1.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) 6.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.45 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 9/9 2/9 +7.00 BHC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.8 69.1 -4.30 VRDN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.97 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE 19.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.07B $2.79B $274.1M BHC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BHC REV VRDN REV BHC GROSS % VRDN GROSS % BHC FCF VRDN FCF
FY 2025 $10.27B $1.02B — — $1.00B -$276.9M
FY 2024 $9.63B $837.3M — — $1.26B -$232.8M
FY 2023 $8.76B $712.5M — — $637.9M -$184.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
VRDN // BETA —